A Study of Motexafin Gadolinium for the Treatment of Chronic Lymphocytic Leukemia (CLL)

Phase 2TerminatedNCT00076401

Pharmacyclics LLC.27 enrolled

Overview

The purpose of this study is to determine if the drug motexafin gadolinium will be an effective treatment for patients who have chronic lymphocytic leukemia (CLL) that has come back after treatment or that has stopped responding to treatment.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Leukemia Leukemia, Lymphocytic, Chronic

Interventions

Motexafin gadoliniumDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * At least 18 years old * Refractory or relapsed CLL * ECOG performance status score of 0, 1, or 2 * Each patient must sign a study-specific informed consent form Exclusion Criteria: Laboratory values of: * Platelet count \<30,000/uL * AST or ALT \>2 x the upper limit of normal (ULN) * Total bilirubin \>2 x ULN * Creatinine \>2.0 mg/dL * Chemotherapy, radiation therapy, immunotherapy, systemic corticosteroids, or systemic biologic anticancer therapy within 21 days before beginning study treatment * Women who are pregnant or lactating

Locations (1)

Ohio State University Medical Center

Columbus, Ohio, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.